Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells $337,932.36 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 1,044 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $323.69, for a total value of $337,932.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $302.46, for a total value of $200,833.44.
• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total transaction of $103,159.04.

BeOne Medicines Price Performance

ONC opened at $327.53 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The firm has a market cap of $35.94 billion, a price-to-earnings ratio of 73.27 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The company has a fifty day simple moving average of $294.53 and a 200 day simple moving average of $308.67.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Institutional Trading of BeOne Medicines

A number of large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new stake in shares of BeOne Medicines during the 2nd quarter valued at $67,657,000. Man Group plc acquired a new position in shares of BeOne Medicines in the 2nd quarter worth $59,031,000. BNP Paribas Financial Markets acquired a new stake in shares of BeOne Medicines during the second quarter worth $38,337,000. First Trust Advisors LP raised its position in shares of BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of BeOne Medicines during the second quarter valued at $26,034,000. 48.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on ONC shares. Leerink Partners increased their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Wells Fargo & Company started coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Citizens Jmp reiterated a “market outperform” rating and issued a $396.00 target price on shares of BeOne Medicines in a research report on Wednesday, July 1st. Finally, Royal Bank Of Canada raised their price objective on shares of BeOne Medicines from $436.00 to $451.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $394.00.

BeOne Medicines News Roundup

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings surpassed expectations: BeOne Medicines reported adjusted earnings of $2.05 per share, well above the $1.40 analyst consensus. The result strengthens the investment case by demonstrating better-than-expected profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: Revenue outlook exceeded forecasts: Management projected fiscal 2026 revenue of $6.6 billion to $6.8 billion, compared with Wall Street’s $6.5 billion expectation. The guidance suggests continued momentum across the company’s oncology portfolio. BeOne Medicines Q2 metrics
• Positive Sentiment: Pipeline progress provided additional support: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially helping accelerate development and regulatory engagement for the candidate. BeOne lands UK Innovation Passport
• Neutral Sentiment: Analyst sentiment remains favorable: Recent coverage maintained predominantly Buy or Overweight ratings, with a reported consensus price target of approximately $394, although the stock’s elevated valuation leaves expectations high.
• Neutral Sentiment: Insider transactions were sales for tax purposes: CFO Aaron Rosenberg sold 1,157 shares worth about $362,000, while SVP Chan Henry Lee sold 1,044 shares worth approximately $338,000. Both transactions were explicitly tied to tax withholding on vested equity awards, reducing their significance as a bearish signal. BeOne CFO SEC filing

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.